

## List of T2B! Immunity against SARS-CoV-2 study group

L.Y.L	Kummer
P.J.	van Dam
E.W.	Stalman
L.	Wieske
F.	Eftimov
A.J.	vd Kooi
J.	Raaphorst
A.H.	Zwinderman
M.	Löwenberg
A.G.	Volkers
G.R.A.M.	D'Haens
R.B.	Takkenberg
T.W.	Kuijpers
S.W.	Tas
P.I.	Spuls
M.W.	Bekkenk
A.H.	Musters
N.F.	Post
A.L.	Bosma
M.L.	Hilhorst
Y.	Vegting
F.J.	Bemelman
M	Steenhuis
T.	Rispens
N.J.M.	Verstegen
S.M.	van Ham
A.	ten Brinke
R.	de Jongh
C.E.	van de Sandt
L.	Kuijper
M.	Duurland
R.R.	Hagen
J.	van den Dijssel
C.	Kreher
A.	Bos
V.	Palomares Cabeza
S.	Keijzer
J.	Boogaard
B.D.	Keijser

O.	Cristianawati
V.A.L.	Konijn
G.	Elias
J.G.	Vallejo
M.J.	van Gils
T.M.	Ashhurst
J.	Killestein
Z.L.E.	van Kempen
A.E.	Voskuyl
B.	Broens
A.	Parra Sanchez
S.	Nejentsev
E.S.	Mirfazeli
G.J.	Wolbink
L	Boekel
A.	Rutgers
K.	de Leeuw
B.	Horváth
J.J.G.M.	Verschuuren
A.M.	Ruiter
L.	van Ouwerkerk
D.	van der Woude
C.F.	Allaart
Y.K.O.	Teng
P.	van Paassen
M.H.	Busch
B.P.	Jallah
E.	Brusse
P.A.	van Doorn
A.E.	Baars
D.J.	Hijnen
C.R.G.	Schreurs
W.L.	van der Pol
H.S.	Goedee
A.C.M.	van Els
J.	de Wit

**Supplement table 1: Overview of specific immunosuppressants and completed surveys**

Table showing specific immunosuppressive regimens and number of completed surveys per autoimmune neuromuscular disease. Shown as number with percentage.

	<b>MG (N=137)</b>	<b>CIDP (N=79)</b>	<b>MMN (N=43)</b>	<b>IIM (N=66)</b>
<b>Medication group</b>				
No immunosuppressant	45 (32.8)	11 (13.9)	0 (0)	2 (3.0)
Anti-CD20+other(s)	0 (0)	1 (1.3)	0 (0)	9 (13.6)
Anti-CD20	0 (0)	1 (1.3)	0 (0)	1 (1.5)
Corticosteroids	20 (14.6)	2 (2.5)	0 (0)	3 (4.5)
Corticosteroids + other	5 (3.6)	2 (2.5)	0 (0)	2 (3.0)
Immunoglobulins	0 (0)	62 (78.5)	43 (100)	0 (0)
Methotrexate	1 (0.7)	0 (0)	0 (0)	7 (10.6)
Mycophenolate mofetil	4 (2.9)	0 (0)	0 (0)	1 (1.5)
Mycophenolate mofetil + corticosteroids	12 (8.8)	0 (0)	0 (0)	9 (13.6)
Methotrexate / purine antagonist + corticosteroids	18 (13.1)	0 (0)	0 (0)	23 (34.8)
Methotrexate / purine antagonist +other	4 (2.9)	0 (0)	0 (0)	1 (1.5)
Other(s)	4 (2.9)	0 (0)	0 (0)	3 (4.5)
Purine antagonist	24 (17.5)	0 (0)	0 (0)	5 (7.6)
<b>Number of completed surveys</b>				
1	137 (100)	79 (100)	43 (100)	66 (100)
2	137 (100)	79 (100)	43 (100)	66 (100)
3	131 (95.6)	76 (96.2)	43 (100)	58 (87.9)
4	127 (92.7)	73 (92.4)	43 (100)	54 (81.8)
5	122 (89.1)	72 (91.1)	43 (100)	51 (77.3)
6	108 (78.8)	71 (89.9)	37 (86.0)	49 (74.2)
7	22 (16.1)	59 (74.7)	33 (76.7)	39 (59.1)

---

	<b>MG (N=137)</b>	<b>CIDP (N=79)</b>	<b>MMN (N=43)</b>	<b>IIM (N=66)</b>
≥8	8 (5.8)	23 (29.1)	18 (41.9)	24 (36.4)

---

CIDP: chronic inflammatory demyelinating polyneuropathy; IIM: idiopathic inflammatory myopathies;  
IQR: interquartile range; MG: myasthenia gravis; MMN: multifocal motor neuropathy